Reducing Off-Target Toxicity in CRISPR Cas9 to Demonstrate Safety & Retain Efficacy
- Unpacking strategies to minimize off-target toxicity in CRISPR Cas9 therapies to equip you with approaches to build a stronger safety profile for regulators
- Leveraging sequencing-based methods to assess gRNA purity, raw material quality, and genomic instability to de-risk your CRISPR therapy
- Benchmarking industry consensus on sequence purity standards for gene editing materials to help you align your analytical strategy with regulatory expectations